SGLT2 inhibitors and GLP1 agonists in Diabetes Type 2
Over the last few years, there have been significant breakthroughs in the management of Type 2 diabetes (T2D). Sodium–glucose...
New Findings Provide Hope for Neuroprotection in Glaucoma
Scientists at Karolinska Institutet and St. Erik Eye Hospital find new ways to treat glaucoma, a common neurodegenerative disease. A...
GLP-1 receptor agonists and/or DPP4 inhibitors: Diabetes drugs may lower the risk of Parkinson’s disease
Parkinson’s disease, the most common neurodegenerative movement disorder has growing prevalence with the age. Due to increasing life expectancy...